BIIB
Price
$128.02
Change
-$2.69 (-2.06%)
Updated
Apr 4, 10:45 AM (EDT)
Capitalization
31.34B
27 days until earnings call
PFE
Price
$23.32
Change
-$0.97 (-3.99%)
Updated
Apr 4, 11:22 AM (EDT)
Capitalization
157.14B
25 days until earnings call
Ad is loading...

BIIB vs PFE

Header iconBIIB vs PFE Comparison
Open Charts BIIB vs PFEBanner chart's image
Biogen
Price$128.02
Change-$2.69 (-2.06%)
Volume$1.05K
Capitalization31.34B
Pfizer
Price$23.32
Change-$0.97 (-3.99%)
Volume$96.22K
Capitalization157.14B
BIIB vs PFE Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. PFE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and PFE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (BIIB: $130.71 vs. PFE: $24.29)
Brand notoriety: BIIB and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 104% vs. PFE: 110%
Market capitalization -- BIIB: $31.34B vs. PFE: $157.14B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, PFE is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 5 bearish.
  • PFE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PFE is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -6.86% price change this week, while PFE (@Pharmaceuticals: Major) price change was -2.88% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was -8.82%.

Reported Earning Dates

BIIB is expected to report earnings on May 01, 2025.

PFE is expected to report earnings on Apr 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($157B) has a higher market cap than BIIB($31.3B). PFE has higher P/E ratio than BIIB: PFE (74.92) vs BIIB (26.95). PFE YTD gains are higher at: -6.930 vs. BIIB (-14.524). PFE has higher annual earnings (EBITDA): 9.56B vs. BIIB (2.04B). PFE has more cash in the bank: 12.7B vs. BIIB (1.05B). BIIB has less debt than PFE: BIIB (7.34B) vs PFE (70.8B). PFE has higher revenues than BIIB: PFE (58.5B) vs BIIB (9.84B).
BIIBPFEBIIB / PFE
Capitalization31.3B157B20%
EBITDA2.04B9.56B21%
Gain YTD-14.524-6.930210%
P/E Ratio26.9574.9236%
Revenue9.84B58.5B17%
Total Cash1.05B12.7B8%
Total Debt7.34B70.8B10%
FUNDAMENTALS RATINGS
BIIB vs PFE: Fundamental Ratings
BIIB
PFE
OUTLOOK RATING
1..100
5777
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6772
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
9698
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (94) in the Biotechnology industry. This means that PFE’s stock grew significantly faster than BIIB’s over the last 12 months.

PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (67) in the Biotechnology industry is in the same range as PFE (72) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.

PFE's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as BIIB (64) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (96) in the Biotechnology industry is in the same range as PFE (98) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBPFE
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
54%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
51%
Momentum
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
71%
MACD
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
46%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
62%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
59%
Advances
ODDS (%)
Bullish Trend 26 days ago
53%
Bullish Trend 5 days ago
57%
Declines
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 9 days ago
60%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
52%
Aroon
ODDS (%)
Bullish Trend 1 day ago
34%
Bullish Trend 1 day ago
50%
View a ticker or compare two or three
Ad is loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EA144.85-0.02
-0.01%
Electronic Arts
UTMD55.07-0.71
-1.27%
Utah Medical Products
SEED1.91-0.04
-2.05%
Origin Agritech Limited
PECO36.06-1.27
-3.40%
Phillips Edison & Company
CARS10.69-0.95
-8.16%
Cars.com